Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | B2M LOH |
Therapy | Ipilimumab |
Indication/Tumor Type | melanoma |
Response Type | predicted - resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
B2M LOH | melanoma | predicted - resistant | Ipilimumab | Clinical Study - Cohort | Actionable | In a retrospective analysis, B2M loss of heterozygosity (LOH) was significantly enriched in pre-treatment biopsies of melanoma patients who did not respond to Yervoy (ipilimumab) compared to those who responded (20/69, 28.9% vs 4/36, 11.1%, p=0.01), and was associated with poorer overall survival (p=0.01) (PMID: 29070816). | 29070816 |
PubMed Id | Reference Title | Details |
---|---|---|
(29070816) | Resistance to checkpoint blockade therapy through inactivation of antigen presentation. | Full reference... |